Page 107 - 《中国药房》2022年16期
P. 107

国产那屈肝素钙注射液在中国健康受试者中的生物等效性及安

        全性研究          Δ


        李 洁 ,宋恒文 ,杨 能 ,邵志超 ,钱春艳 (1.常州市第一人民医院临床试验机构办公室,江苏 常州
               1*
                         2
                                  1
                                          2
                                                   1 #
        213000;2.常州千红生化制药股份有限公司,江苏 常州 213125)
        中图分类号 R969.1         文献标志码 A           文章编号 1001-0408(2022)16-2017-05
        DOI  10.6039/j.issn.1001-0408.2022.16.18

        摘   要  目的 评价健康成年受试者皮下注射两种那屈肝素钙注射液的生物等效性和安全性。方法 共纳入成年健康受试者 24
        例,按区组随机化法以1 ∶ 1分配到TR(受试制剂-参比制剂)组和RT(参比制剂-受试制剂)组。采用随机、开放、单剂量、双周期交
        叉设计,两组受试者均于每个周期的第1天空腹皮下注射受试制剂或参比制剂6 150 AⅩaIU,第2周期交叉给药,清洗期为7 d。于给
        药前后不同时间点采集血样,采用发色底物法测定人血浆样品中各制剂的抗凝血因子Ⅹa(Anti-Ⅹa)活性和抗凝血因子Ⅱa
       (Anti-Ⅱa)活性,按非房室模型计算药效动力学参数并进行生物等效性评价;同时记录受试者不良事件发生情况。结果 给药后,
        受试制剂和参比制剂Anti-Ⅹa活性的半衰期(t1/2 )分别为(4.87±1.06)、(4.03±1.00)h,达峰时间(tmax )分别为4.50(2.00,8.00)、5.50
       (2.50,8.00)h,Anti-Ⅹa活性最大值(Anti-Ⅹamax )分别为(0.66±0.12)、(0.56±0.11)IU/mL;受试制剂和参比制剂Anti-Ⅱa活性的t1/2
        分别为(3.64±1.60)、(5.74±7.23)h,tmax分别为4.00(2.50,8.00)、4.00(2.00,8.00)h,Anti-Ⅱa活性最大值均为(0.10±0.03)IU/mL;
        两制剂 Anti-Ⅹamax、活性-时间曲线下面积(AUEC0 - t、AUEC0 - ∞)几何均值比的 90%置信区间分别为 110.98%~123.50%、
        112.11%~121.24%、111.57%~120.00%。试验过程中,有14例受试者发生19例次轻度不良事件,其中血肿、紫癜、斑丘疹可能与
        药物有关;未见严重的不良事件发生。结论 国产那屈肝素钙注射液与参比制剂生物等效,两药的安全性均较好。
        关键词 那屈肝素钙注射液;生物等效性;安全性评价

        Bioequivalence and safety evaluation of domestic Nadroparin calcium injection in Chinese healthy volunteers
        LI Jie ,SONG Hengwen ,YANG Neng ,SHAO Zhichao ,QIAN Chunyan(1. GCP Office of the First People’s
                                                                         1
                                                          2
                                          1
             1
                             2
        Hospital of Changzhou,Jiangsu Changzhou 213000,China;2. Changzhou Qianhong Bio-Pharma Co.,Ltd.,
        Jiangsu Changzhou 213125,China)
        ABSTRACT OBJECTIVE To evaluate the bioequivalence and safety of two kinds of Nadroparin calcium injection in healthy
        Chinese volunteers by subcutaneous injection. METHODS According to the block randomization method,24 Chinese healthy adult
        volunteers were included and divided into TR (test preparation-reference preparation) group and RT (reference preparation-test
        preparation)group at a ratio of 1 ∶ 1. A randomized,open-labelled,single-dose and two-cycle crossover study was designed,the fasting
        subjects of two groups were given test or reference preparation 6 150 A Ⅹ aIU subcutaneously on the first day of each cycle and
        exchanged in the second cycle,and the wash-out period was 7 days. The blood samples were collected at different time points before
        and after administration. The activity of anti-coagulant factor Ⅹ a(Anti- Ⅹ a)and Anti- Ⅱ a in human plasma were determined by
        chromogenic substrate method,and the pharmacodynamic parameters were calculated according to the non-atrioventricular model and
        the bioequivalence was evaluated. The occurrence of adverse events(AEs)was recorded. RESULTS After administration,the main
        pharmacodynamic parameters for Anti-Ⅹa activity of test preparation and reference preparation were as follows:t1/2 were(4.87±1.06)
        and(4.03±1.00)h,tmax were 4.50(2.00,8.00)and 5.50(2.50,8.00)h,Anti-Ⅹamax were(0.66±0.12)and(0.56±0.11)IU/mL;main

        pharmacodynamic parameters of Anti-Ⅱa activity of two preparations were as follows:t1/2 were(3.64±1.60)and(5.74±7.23)h,tmax
        were 4.00(2.50,8.00)and 4.00(2.00,8.00)h,Anti-Ⅱamax were both(0.10±0.03)IU/mL. The values of 90%confidence interval of
        geometric mean ratio of Anti-Ⅹamax,AUEC0 - t and AUEC0 - ∞ were 110.98%-123.50%,112.11%-121.24%and 111.57%-120.00%,
        respectively. During experiment,14 subjects reported 19 cases of mild AEs,among which hematoma,purpura and maculopapular rash
                                                           may be related to drugs; no serious AEs were observed.
           Δ 基金项目 江苏省医院协会/江苏现代医院管理研究中心医院管
                                                           CONCLUSIONS The domestic Nadroparin calcium injection is
        理创新研究课题(No.JSYGY-3-2021-664);常州市科技计划(应用基础
                                                           bioequivalent to the reference preparation,and both of them
        研究指导性)项目(No.CJ20209024)
           *第一作者 副主任药师,硕士。研究方向:临床药理学、临床试验                  show good safety.
        项目管理。电话:0519-68870885。E-mail:Lavendercz@sina.com   KEYWORDS Nadroparin calcium injection;bioequivalence;
           # 通信作者 主任药师。研究方向:临床试验、临床药学。电话:                  safety evaluation
        0519-68870885。E-mail:helenaries81325@163.com


        中国药房    2022年第33卷第16期                                            China Pharmacy 2022 Vol. 33 No. 16  ·2017 ·
   102   103   104   105   106   107   108   109   110   111   112